Funding for this research was provided by:
U.S. Department of Veterans Affairs (1I01CX001842, 1I01CX000565)
National Institute on Aging (P30 AG062429, R01 AG063782, R01 AG049810, R01 AG054049)
Alzheimer's Association (AARG-18-566254)
Received: 4 January 2021
Accepted: 31 May 2021
First Online: 1 July 2021
: All procedures were approved by the Institutional Review Boards at UCSD. Written informed consent was obtained from every research participant according to the Declaration of Helsinki and the Belmont Report.
: Not applicable.
: D. Galasko serves as an editor for Alzheimer’s Research and Therapy; is a consultant for Biogen, Inc., Fujirebio, Inc., and Amprion, Inc.; and serves on a Data Safety Monitoring Board for Cognition Therapeutics. D.P. Salmon serves as a paid consultant for Takeda Pharmaceuticals, Inc.; Aptinyx, Inc.; and Biogen, Inc. M. Bondi receives royalties from Oxford University Press. Other authors declare that they have no competing interests.